Ulinastatin- and thymosin α1-based immunomodulatory strategy for sepsis: A meta-analysis

International Immunopharmacology

Volumn 29, Issue 2, 2015, Pages 377-382

  Han, Dong ^a   Shang, Wenli ^a   Wang, Guizuo ^a   Sun, Li ^a   Zhang, Yingying ^b   Wen, Hongxia ^a   Xu, Lingbin ^a  

^a SHAANXI PROVINCIAL PEOPLE S HOSPITAL   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Meta analysis; Sepsis; Thymosin 1; Ulinastatin

Indexed keywords

INTERLEUKIN 6; THYMOSIN ALPHA1; TUMOR NECROSIS FACTOR ALPHA; ULINASTATIN; GLYCOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOLOGIC FACTOR; THYMOSIN;

ARTICLE; ARTIFICIAL VENTILATION; DRUG EFFICACY; FOLLOW UP; HUMAN; IMMUNOMODULATION; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SEPSIS; ANALOGS AND DERIVATIVES;

GLYCOPROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOLOGIC FACTORS; SEPSIS; THYMOSIN;

EID: 84948470722     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2015.10.026     Document Type: Article

References (37)

1. D.C. Angus, W.T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M.R. Pinsky Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care Crit. Care Med. 29 2001 1303 1310
2. J.L. Vincent, J. Rello, J. Marshall, E. Silva, A. Anzueto, C.D. Martin, and et al. International study of the prevalence and outcomes of infection in intensive care units JAMA 302 2009 2323 2329
3. G. Kumar, N. Kumar, A. Taneja, T. Kaleekal, S. Tarima, E. McGinley, and et al. Nationwide trends of severe sepsis in the 21st century (2000-2007) Chest 140 2011 1223 1231
4. J.C. Andreu Ballester, F. Ballester, A. Gonzalez Sanchez, A. Almela Quilis, E. Colomer Rubio, and O.C. Penarroja Epidemiology of sepsis in the Valencian Community (Spain), 1995-2004 Infect. Control Hosp. Epidemiol. 29 2008 630 634
5. V.Y. Dombrovskiy, A.A. Martin, J. Sunderram, and H.L. Paz Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003 Crit. Care Med. 35 2007 1244 1250
6. R. Ferrer, A. Artigas, D. Suarez, E. Palencia, M.M. Levy, A. Arenzana, and et al. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study Am. J. Respir. Crit. Care Med. 180 2009 861 866
7. V.M. Ranieri, B.T. Thompson, P.S. Barie, J.F. Dhainaut, I.S. Douglas, S. Finfer, and et al. Drotrecogin alfa (activated) in adults with septic shock N. Engl. J. Med. 366 2012 2055 2064
8. D. Annane, J.F. Timsit, B. Megarbane, C. Martin, B. Misset, B. Mourvillier, and et al. Recombinant human activated protein C for adults with septic shock: a randomized controlled trial Am. J. Respir. Crit. Care Med. 187 2013 1091 1097
9. S.M. Opal, P.F. Laterre, B. Francois, S.P. LaRosa, D.C. Angus, J.P. Mira, and et al. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial JAMA 309 2013 1154 1162
10. J.L. Vincent, J.C. Marshall, R.P. Dellinger, S.G. Simonson, K. Guntupalli, M.M. Levy, and et al. Talactoferrin in severe sepsis: results from the phase II/III oral tAlactoferrin in severe sepsIS trial Crit. Care Med. 43 2015 1832 1838
11. J. Cohen, S. Opal, and T. Calandra Sepsis studies need new direction Lancet Infect. Dis. 12 2012 503 505
12. S.C. Williams After Xigris, researchers look to new targets to combat sepsis Nat. Med. 18 2012 1001
13. D.C. Angus The search for effective therapy for sepsis: back to the drawing board? JAMA 306 2011 2614 2615
14. K.M. Kaukonen, M. Bailey, D. Pilcher, D.J. Cooper, and R. Bellomo Systemic inflammatory response syndrome criteria in defining severe sepsis N. Engl. J. Med. 372 2015 1629 1638
15. M.J. Pugia, and J.A. Lott Pathophysiology and diagnostic value of urinary trypsin inhibitors Clin. Chem. Lab. Med. CCLM/FESCC 43 2005 1 16
16. R. Sharony, P.J. Yu, J. Park, A.C. Galloway, P. Mignatti, and G. Pintucci Protein targets of inflammatory serine proteases and cardiovascular disease J. Inflamm. (London, England) 7 2010 45
17. K. Kessenbrock, T. Dau, and D.E. Jenne Tailor-made inflammation: how neutrophil serine proteases modulate the inflammatory response J. Mol. Med. (Berlin, Germany) 89 2011 23 28
18. H. Shigetomi, A. Onogi, H. Kajiwara, S. Yoshida, N. Furukawa, S. Haruta, and et al. Anti-inflammatory actions of serine protease inhibitors containing the Kunitz domain Inflamm. Res. Off. J. Eur. Histamine Res. Soc. 59 2010 679 687 [et al.]
19. Y.P. Lim, K. Bendelja, S.M. Opal, E. Siryaporn, D.C. Hixson, and J.E. Palardy Correlation between mortality and the levels of inter-alpha inhibitors in the plasma of patients with severe sepsis J. Infect. Dis. 188 2003 919 926
20. A.L. Goldstein, A. Guha, M.M. Zatz, M.A. Hardy, and A. White Purification and biological activity of thymosin, a hormone of the thymus gland Proc. Natl. Acad. Sci. U. S. A. 69 1972 1800 1803
21. H.Y. Lin Clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with ulinastatin and maipuxin Zhonghua Yi Xue Za Zhi 87 2007 451 457
22. Y. Zhang, H. Chen, Y.M. Li, S.S. Zheng, Y.G. Chen, L.J. Li, and et al. Thymosin alpha1- and ulinastatin-based immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria J. Infect. Dis. 198 2008 723 730
23. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann. Intern. Med. 151 2009 264 269 W64
24. A.S. Detsky, C.D. Naylor, K. O'Rourke, A.J. McGeer, and K.A. L'Abbe Incorporating variations in the quality of individual randomized trials into meta-analysis J. Clin. Epidemiol. 45 1992 255 265
25. S.W. Huang, J. Chen, B. Ouyang, C.H. Yang, M.Y. Chen, and X.D. Guan Immunotherapy improves immune homeostasis and increases survival rate of septic patients Chin. J. Traumatol. = Zhonghua Chuang Shang Za Zhi/Chin. Med. Assoc. 12 2009 344 349
26. Y. Li, H. Chen, X. Li, W. Zhou, M. He, M. Chiriva-Internati, and et al. A new immunomodulatory therapy for severe sepsis: ulinastatin plus thymosin {alpha} 1 J. Intensive Care Med. 24 2009 47 53
27. L. Su, F.S. Meng, Y.Q. Tang, Q. Wen, Y.S. Liu, L.Q. Tang, and et al. [Clinical effects of ulinastatin and thymosin alpha1 on immune-modulation in septic patients] Zhongguo Wei Zhong Bing Ji Jiu Yi Xue = Chin. Crit. Care Med. = Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 21 2009 147 150
28. J.L. Vincent, S.M. Opal, J.C. Marshall, and K.J. Tracey Sepsis definitions: time for change Lancet (London, England) 381 2013 774 775
29. R.P. Wenzel, and M.B. Edmond Septic shock - evaluating another failed treatment N. Engl. J. Med. 366 2012 2122 2124
30. R.S. Munford, and J. Pugin Normal responses to injury prevent systemic inflammation and can be immunosuppressive Am. J. Respir. Crit. Care Med. 163 2001 316 321
31. W. Xiao, M.N. Mindrinos, J. Seok, J. Cuschieri, A.G. Cuenca, H. Gao, and et al. A genomic storm in critically injured humans J. Exp. Med. 208 2011 2581 2590
32. R.S. Hotchkiss, G. Monneret, and D. Payen Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach Lancet Infect. Dis. 13 2013 260 268
33. R.S. Hotchkiss, and I.E. Karl The pathophysiology and treatment of sepsis N. Engl. J. Med. 348 2003 138 150
34. D.J. Stearns-Kurosawa, M.F. Osuchowski, C. Valentine, S. Kurosawa, and D.G. Remick The pathogenesis of sepsis Annu. Rev. Pathol. 6 2011 19 48
35. E. Abraham, M.P. Glauser, T. Butler, J. Garbino, D. Gelmont, P.F. Laterre, and et al. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 study group JAMA 277 1997 1531 1538
36. M.F. Osuchowski, K. Welch, J. Siddiqui, and D.G. Remick Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality J. Immunol. 177 2006 1967 1974
37. A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gotzsche, J.P. Ioannidis, and et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Ann. Intern. Med. 151 2009 W65 W94